

INVITATION

**SYMPOSIUM:
BRAIN DISEASES
– WHY TO INVEST
IN FINLAND**



WELCOME

SYMPOSIUM: BRAIN DISEASES – WHY TO INVEST IN FINLAND

Faculty of Medicine, University of Helsinki, Pharma Industry Finland,
Herantis Pharma Oyj and Biogen Finland Oy have a pleasure
to invite you to the Symposium:

**Brain Diseases – Why to invest in Finland
on the 12th of November at 9.00–13.00.**

The Symposium will take place at Haartman Institute, Lecture Hall 1
University of Helsinki (Haartmaninkatu 3, 00290 Helsinki).

The Symposium aims to increase awareness of brain diseases and their impact,
emphasize the great untapped potential of Finland in academic research
of brain disease and define the strengths
and weaknesses of the Finnish healthcare environment for international
investments and collaboration.

Welcome!

<i>Risto Renkonen</i>	<i>Jussi Merikallio</i>	<i>Pekka Simula</i>	<i>Marco Hautalahti</i>
Dean	CEO	CEO	General Manager
Faculty of Medicine, University of Helsinki	Pharma Industry Finland	Herantis Pharma Oyj	Biogen Finland Oy

RSVP by November 6th at www.helsinki.fi/insight/braindiseases
Please register soon — seats are limited.

Additional information:
marco.hautalahti@biogen.com, +358 400 493 613
heidil.lehmuskumpu@helsinki.fi, +358 50 416 0750

PROGRAMME

09.00–09.10	Welcome and opening words Dean Risto Renkonen, University of Helsinki
09.10–09.30	Healthcare sector and economic growth Minister of Economic Affairs Olli Rehn, Ministry of Employment and the Economy
09.30–09.50	Brain diseases: How Finland transforms a major health challenge to benefit patients and society Professor Anu Wartiovaara, University of Helsinki
09.50–10.10	Finnish healthcare environment for investors and collaborators – challenges and opportunities CEO Jussi Merikallio, Pharma Industry Finland
10.10–10.30	Brain diseases in Finland. Case ALS Senior Investigator Bryan Traynor, National Institutes of Aging
10.30–11.00	Coffee break
11.00–11.20	Brain diseases in Finland. Case Multiple Sclerosis Professor Pentti Tienari, University of Helsinki, HUS
11.20–11.40	Basic research translated into therapy for brain diseases CEO Pekka Simula, Herantis Pharma Oyj
11.40–12.00	Brain disease research and development in Europe VP Medical Maha Radhakrishnan, Biogen
12.00–12.20	Growth, employment and competitiveness in European Union – Focus and new opportunities Vice-President Jyrki Katainen, European Commission
12.20–13.00	Round table discussion – Brain diseases and why to invest in Finland All speakers and professor Risto O. Roine, University of Turku
13.00–14.00	Lunch Biomedicum Helsinki 1, B1 lobby (Haartmaninkatu 8)
14.00–17.00	Additional programme for neurologists: Clinical trials and collaboration in Finland Organized by Biogen Finland Oy Haartman Institute, Lecture Hall 1 (Haartmaninkatu 3)



HERANTIS
PHARMA



LÄÄKETEOLLISUUS
PHARMA INDUSTRY FINLAND



UNIVERSITY OF HELSINKI